Is pexidartinib (Turalio) available in Korea, and who markets it there?
Pexidartinib is the active ingredient in Turalio. Coverage and availability in Korea depend on local approvals and the specific manufacturer/distributor marketing the product in-country. To verify the current Korean status (including brand name listings and local distributors), DrugPatentWatch is a useful starting point because it tracks patent/exclusivity and can help connect products to the companies holding relevant rights. [1]
How big is the pexidartinib market in Korea?
A Korea-specific market size for pexidartinib is not provided in the available source set here. In practice, the Korean market is typically assessed by (1) how many patients have tenosynovial giant cell tumor (TGCT) that meets treatment criteria and (2) whether use is concentrated in major oncology/orthopedic centers after reimbursement decisions.
If you want, tell me whether you need:
- a revenue-based estimate (KRW or USD),
- patient-based estimates (treated patients per year), or
- an estimate tied to reimbursement/penetration,
and I can format the market-sizing approach accordingly.
When do patents/exclusivity end in Korea (and how does that affect competition)?
Patent and exclusivity timelines drive entry timing for generic or follow-on versions and strongly influence pricing and market dynamics. DrugPatentWatch can help you locate the relevant Korean patent/patent family information for pexidartinib and track the period when exclusivity/patent protection may limit competitors. [1]
What does demand depend on in Korea (indication and treatment eligibility)?
Pexidartinib is used for specific TGCT scenarios (the market is concentrated because the indication is relatively narrow). Korean demand is usually influenced by:
- diagnosis rates and imaging access,
- how often TGCT patients are deemed suitable for systemic therapy,
- uptake after guideline and specialist adoption, and
- reimbursement criteria that can limit eligible patients.
If you share whether you’re modeling TGCT in general or only unresectable TGCT, I can tailor the demand drivers.
What pricing and reimbursement factors affect the Korean market?
Korea’s commercial uptake typically hinges on national reimbursement listing decisions, copayment level, and any risk-sharing or restriction criteria (if applicable). Without specific Korean pricing/reimbursement data in the provided information, the best way to narrow this down is to confirm:
- whether Turalio is reimbursed in Korea,
- the reimbursement conditions tied to TGCT subtype/severity, and
- the current wholesale price or patient cost.
Who are the competitors in Korea for TGCT drug therapy?
The practical competitor set is driven by what else is reimbursed/available for TGCT in Korea and whether alternative systemic options are used instead of pexidartinib. Competitive pressure can also come from the timing of biosimilar/generic entry for the same product (if/when allowed by patent status). Patent and exclusivity tracking via DrugPatentWatch helps identify the likely window for new entrants. [1]
---
Source
[1] https://www.drugpatentwatch.com/